
Electra Therapeutics, Inc.
36
Recent analyst coverage initiations by JP Morgan and Cantor Fitzgerald with overweight ratings highlight increased market attention on Electra Therapeutics in October 2026.
- JP Morgan initiated coverage of Electra Therapeutics with an overweight rating on October 22, 2026, indicating positive analyst interest in the company [N1].
- Cantor Fitzgerald initiated coverage of Electra Therapeutics with an overweight rating on October 13, 2026, reflecting growing market attention [N2].
- The company filed its latest 10-Q on November 12, 2026, disclosing financial results for the quarter ended September 30, 2026, including liquidity and net loss figures [S1].
Electra Therapeutics, Inc. is a company with publicly available financial disclosures through SEC filings. As of the third quarter of 2026, the company holds substantial liquid assets and maintains a strong liquidity position with a current ratio near 24. The company reported no revenue and incurred a net loss during this period. Recent analyst coverage by major financial institutions indicates market interest, though detailed business model and sector information are not disclosed in the available data.
Electra Therapeutics, Inc. is a publicly reporting company with recent SEC filings disclosing strong liquidity as of September 30, 2026, including $256.4 million in cash and $146.1 million in short-term investments. The company reported no revenue and a net loss of $23.9 million for the quarter. Recent analyst coverage was initiated by JP Morgan and Cantor Fitzgerald with overweight ratings in October 2026. Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
The initiation of analyst coverage by reputable firms suggests recognition of potential value or strategic positioning. The company's strong liquidity position provides financial flexibility to support operations or development activities.
The absence of revenue and ongoing net losses highlight operational challenges. Limited public disclosure on business activities and sector focus creates uncertainty about the company's path to profitability and market relevance.
There is insufficient public information to assess Electra Therapeutics' competitive advantages or moat. The lack of disclosed sector, industry, and detailed business model information limits visibility into its market positioning or proprietary strengths.
• Operational Risk: The company reported no revenue and a net loss for the latest quarter, indicating ongoing operational challenges.
• Information Transparency Risk: Lack of detailed disclosure on business model, sector, and industry limits stakeholder understanding and assessment of company prospects.
• Liquidity Risk: While current liquidity is strong, sustaining operations without revenue may increase risk if capital resources are depleted.
Business trends: The company maintains strong liquidity with no reported revenue and ongoing net losses, while attracting analyst coverage.
Execution milestones: Recent initiation of analyst coverage and quarterly SEC filings provide transparency on financial status.
Key risks: Operational losses, limited business model disclosure, and reliance on capital resources pose challenges to visibility and sustainability.
Low visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Electra Therapeutics, Inc. is a publicly reporting company with SEC filings including a 10-Q filed on 2026-11-12 covering the period ending 2026-09-30.
- As of 2026-09-30, Electra Therapeutics reported cash and cash equivalents of $256.4 million and short-term investments of $146.1 million, totaling $402.5 million in liquid assets.
- Current assets were $406.9 million and current liabilities were $17.0 million as of 2026-09-30, resulting in a current ratio of 23.97 and a cash ratio of 23.71, indicating strong liquidity.
- The company reported zero revenue and a net loss of $23.9 million for the quarter ending 2026-09-30, with basic and diluted earnings per share of -$3.47.
- Recent analyst coverage was initiated by JP Morgan with an overweight rating on 2026-10-22 and by Cantor Fitzgerald with an overweight rating on 2026-10-13.
- No disclosed sector or industry classification is available in the provided data.
- The company’s financial figures are summarized from the latest available SEC filings and are provided for informational purposes only.
Generated 2026-11-15
- S1 | 2026-11-12 | 10-Q
- N1 | 2026-10-22 | www.nasdaq.com | JP Morgan Initiates Coverage of Electra Therapeutics at Overweight | https://www.nasdaq.com/articles/jp-morgan-initiates-coverage-electra-therapeutics-overweight
- N2 | 2026-10-13 | www.nasdaq.com | Cantor Fitzgerald Initiates Coverage of Electra Therapeutics with Overweight Rating | https://www.nasdaq.com/articles/cantor-fitzgerald-initiates-coverage-electra-therapeutics-overweight-rating
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


